Susanne Schultze-Seemann

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Docetaxel (DOC) is used for the first-line treatment of castration resistant prostate cancer (CPRC). However, the therapeutic effects are limited, only about one half of patients respond to the therapy and severe side effects possibly lead to discontinuation of treatment. Therefore, actual research is focused on the development of new DOC-based combination(More)
  • 1